18KIT
The investigators, led by Satish Garg, MD, from the
University of Colorado, Aurora, and Editor-in-Chief of
Diabetes Technology & Therapeutics, reported that inclinic glucose
manipulations and frequent blood glucose
sampling confirmed accurate readings across different
glucose ranges (euglycaemia, hypoglycaemia, and
hyperglycaemia), and during rapid glucose concentration
change. The mean absolute relative difference (MARD)
values were 8.1% for arm-placed sensors and <9.2% for
abdomen-placed sensors. To the best of our knowledge,
G7 is the most accurate sensor with MARD of 8.1% for
the arm-placed CGM. In addition, G7 is significantly
smaller than G6 (by 60%) and introduces new features
such as sensor/transmitter integration with a simplified
insertion process," state the investigators. "The enhanced
features of G7 are likely to increase clinical adoption,
encourage sustained use, and reduce the burden of
diabetes management."
Happy times
In the US, Dexcom CGM has gained approval by the FDA
for use in hospital settings, allowing physicians to be able
to remote monitor patients on their wards.
Expanding the number of devices that Dexcom talks
to, always part of the plan, so now Happy Bob has joined
the gang, the integration gives a playful way to engage
with glucose readings, with the Helsinki-based company
Happy Bob users can view their glucose values by quickly
glancing at their Apple Watch or iPhone widget, create
groups for support, collect stars and receive timesensitive
information and push notifications.
Users can also see their historical data in the app
for longer than 24 hours, access the expanded view,
see insights on their desktop, and laugh at the in-app
personalized messaging. Created by and for people
with diabetes, Team Happy Bob aimed to developed the
app to alleviates the stress of daily management and
glycaemic control.
www.dexcom.com/uk
GLOOKO
Glooko Inc., a leading provider of remote patient
monitoring and data management solutions for diabetes
and related chronic conditions, today announced the
acquisition of DiabNext, a Paris-based company whose
digital health platform helps people with diabetes better
manage their conditions and connects to their healthcare
providers, so they can work together to improve health
outcomes.
DiabNext's mobile app complements Glooko's product
portfolio and tracks diabetes data so that physicians
can collaborate with their patients to monitor individual
patient data and provide remote care. DiabNext already
has a strong presence in France, and under the Glooko
product umbrella, can significantly increase the number
of patients and healthcare providers in the territory and
expand remote patient monitoring offerings.
"We are very pleased to welcome the v team to Glooko
and especially excited to add their well-regarded product
to Glooko's portfolio, along with their expertise in the
diabetes community in France," said Russ Johannesson,
CEO of Glooko. "The addition of DiabNext expands our
offerings with a unique platform that can help us better
customize the patient experience and improve health
outcomes for people with diabetes. Glooko's acquisition
of DiabNext further cements our commitment to increase
our global presence and continue to drive innovative
solutions."
The DiabNext team has joined the Glooko team in the
company's Paris office and will offer both platforms to the
French market. Glooko's goal is to serve more patients
with diabetes as well as related chronic conditions.
The former CEO of DiabNext, Laurent Nicolas, is the
Managing Director and will lead the efforts in France.
"The DiabNext team is excited to be part of Glooko.
We appreciate the value Glooko places on the product
solutions developed for the unique needs of the French
market," said Laurent Nicolas. "Not only will this allow us
to continue to serve the diabetes community, but with
Glooko's resources and capabilities in device integration,
we can now offer more tools to help healthcare
professionals provide better care across diabetes-related
chronic conditions for the patients they serve."
All existing patients, hospitals and clinics currently
using the DiabNext product will continue to be supported
on the platform.
www.glooko.com
MEDTRUM
Medtrum is a Shanghai-based company founded in
2008. The name 'Medtrum' is a combination of the words
'medical' and 'spectrum' (the whole world), which shows
its ambition to transform global medical tech. Medtrum
has been developing European market since 2015 and
Dexcom now talks to the Happy Bob app